Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
Published Medicine, Inc. EDIT-101 demonstrates a favorable safety profile across all dose cohorts Preliminary efficacy signals of steady improvement in BCVA plus additional efficacy endpoints seen in homozygous patients Realization of a proof of concept and identification of a population of stakeholders Given the low population, the Company will suspend recruitment in the BRILLIANCE trial …